Among them, KRAS, a Kirsten ras oncogene homolog, was reported to have functional synergy with HBx in HCC initiation and progression 62, and FOXO1 has been proposed to inhibit EMT transcriptional activators in HCC 63, 64. The gene discussed is KRAS; the disease is hepatocellular carcinoma.